Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects
approximately one-quarter of the global adult population, causing a substantial burden of ill …

The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …

Nonalcoholic fatty liver disease (NAFLD), including its more severe manifestation,
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …

The liver is the sixth most common site of primary cancer in humans, and generally arises in
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide and a leading cause of death in cirrhosis. The prognosis in HCC is poor, with …

One quarter of the global population is estimated to have nonalcoholic fatty liver disease
(NAFLD). The incidence of nonalcoholic steatohepatitis (NASH) is projected to increase by …

Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …

Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver
disease and affects nearly a quarter of the global population. The objective of this work was …